

Rev 1: September 2018
FSNRef: FSN-2022-006

Date: 14 June 2022

Urgent Field Safety Notice

Thermo Scientific™ IDEIA™ Lyme Neuroborreliosis (K602811-2)

For Attention of*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*
--

E.mail : mbd.vigilance@thermofisher.com

Telephone: +44(0) 1256 841 144

Fax: +44(0) 1256 479525

Rev 1: September 2018
FSN Ref: FSN-2022-006

Urgent Field Safety Notice (FSN)

Thermo Scientific™ IDEIA™ Lyme Neuroborreliosis

1. Information on Affected Devices*	
1.	1. Device Type(s)* IVD
1.	2. Commercial name(s) Thermo Scientific IDEIA Lyme Neuroborreliosis (K602811-2)
1.	3. Unique Device Identifier(s) (UDI-DI) 05032384501854
1.	4. Primary clinical purpose of device(s)* Thermo Scientific™ IDEIA™ Lyme Neuroborreliosis test is an enzyme immunoassay for the detection of intrathecally produced human IgG and IgM antibodies to <i>Borrelia burgdorferi</i> sensu lato. The kit is intended as an aid in the diagnosis of Lyme Neuroborreliosis.
1.	5. Device Model/Catalogue/part number(s)* K602811-2
1.	6. Software version N/A
1.	7. Affected serial or lot number range 3346025, 3382296, 3399374
1.	8. Associated devices N/A

2. Reason for Field Safety Corrective Action (FSCA)*	
2.	1. Description of the product problem* An internal technical investigation has determined that when testing at 20°C, K602811-2 IDEIA Lyme Neuroborreliosis Lots. 3346025, 3382296 and 3399374, results in the IgM positive control fall below the IFU criteria (>0.5) therefore causing an invalid test result.
2.	2. Hazard giving rise to the FSCA* Delay to patient treatment
2.	3. Probability of problem arising High
2.	4. Predicted risk to patient/users 1. There should be no immediate or long-term health consequences from use of K602811-2 IDEIA Lyme Neuroborreliosis Lots. 3346025, 3382296 and 3399374. The clinical risk should therefore be considered as minor as low positive control invalidates the assay.
2.	5. Further information to help characterise the problem N/A
2.	6. Background on Issue Fifteen complaints have been received from 11 customers stating that IgM control is 'too low'. All three lots use the same IgM control.

Rev 1: September 2018
FSN Ref: FSN-2022-006

2.	7. Other information relevant to FSCA		
	Lot	DOM (YYYY-MM-DD)	Exp. Date (YYYY-MM-DD)
	3346025	2021-12-08	2023-03-31
	3382296	2021-12-14	2023-04-30
	3399374	2022-02-25	2023-04-30

3. Type of Action to mitigate the Risk*		
3.	1. Action To Be Taken by the User* <input type="checkbox"/> Identify Device <input type="checkbox"/> Quarantine Device <input type="checkbox"/> Return Device <input checked="" type="checkbox"/> Destroy Device <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Follow patient management recommendations <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU) <input type="checkbox"/> Other <input type="checkbox"/> None	
3.	2. By when should the action be completed?	Immediately
3.	3. Particular considerations for: IVD Is follow-up of patients or review of patients' previous results recommended? No We request that the requirement for review of reported test results should be determined by the appropriate technical expert.	
3.	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3.	5. Action Being Taken by the Manufacturer <input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> Other <input type="checkbox"/> None	
3	6. By when should the action be completed?	As soon as possible
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet? Choose an item. Choose an item.	

Rev 1: September 2018
FSN Ref: FSN-2022-006

4. General Information*		
4.	1. FSN Type*	New
4.	2. For updated FSN, reference number and date of previous FSN	N/A
4.	3. For Updated FSN, key new information as follows:	
	N/A	
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet
4	5. If follow-up FSN expected, what is the further advice expected to relate to:	
	N/A	
4	6. Anticipated timescale for follow-up FSN	N/A
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Thermo Fisher Scientific
	b. Address	Remel Europe Ltd, Clipper Boulevard West Dartford Kent DA26PT
	c. Website address	www.thermofisher.com
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *	
4.	9. List of attachments/appendices:	Customer response form
4.	10. Name	'''
	Signature	...

Transmission of this Field Safety Notice	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate)</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*</p>

Rev 1: September 2018
FSN Ref: FSN-2022-006

Customer Reply Form

1. Field Safety Notice (FSN) information			
FSN Reference number*		2022-006	
FSN Date*		14 June 2022	
Product/ Device name*		Thermo Scientific™ IDEIA™ Lyme Neuroborreliosis	
Product Code(s)		K602811-2	
Batch/Serial Number (s)		3346025, 3382296, 3399374	
2. Customer Details			
Account Number			
Organisation Name*			
Organisation Address*			
Department/Unit			
Shipping address if different to above			
Contact Name*			
Title or Function			
Telephone number*			
Email*			
3. Customer action undertaken on behalf of Healthcare Organisation			
<input type="checkbox"/>	I confirm receipt of the Field Safety Notice and that I read and understood its content.		
<input type="checkbox"/>	I performed all actions requested by the FSN.		
<input type="checkbox"/>	The information and required actions have been brought to the attention of all relevant users and executed.		
<input type="checkbox"/>	I have returned affected devices - enter number of devices returned and date complete or N/A	Qty:	Lot/Serial Number: Date Returned (DD/MM/YY)
		Comments:	
<input type="checkbox"/>	I have destroyed affected devices – enter number destroyed and date complete.	Qty:	Lot/Serial Number: Date Returned (DD/MM/YY)
		Qty	Credit <input type="checkbox"/> Replacement <input type="checkbox"/>
		Comments:	
<input type="checkbox"/>	No affected devices are available for return/ destruction		
<input type="checkbox"/>	Other Action (Define):		
<input type="checkbox"/>	I do not have any affected devices.		
<input type="checkbox"/>	I have a query please contact me (e.g. need for replacement of the product).		
Print Name*			
Signature*			
Date*			

Rev 1: September 2018
FSN Ref: FSN-2022-006

4. Return acknowledgement to sender	
Email	MBD.vigilance@thermofisher.com
Telephone Number & Fax	Tel : +44(0) 1256 841144 Fax : +44(0) 1256 479525
Postal Address	
Deadline for returning the reply form*	12 July 2022

Mandatory fields are marked with *

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.